{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=KRAS+G12C+Lung+Cancer&page=4", "query": { "condition": "KRAS G12C Lung Cancer", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 73, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=KRAS+G12C+Lung+Cancer&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=KRAS+G12C+Lung+Cancer&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-03T13:50:02.470Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04303780", "title": "Study to Compare AMG 510 \"Proposed INN Sotorasib\" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "KRAS p, G12c Mutated /Advanced Metastatic NSCLC" ], "interventions": [ { "name": "AMG 510", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 345, "start_date": "2020-06-04", "completion_date": "2026-06-24", "has_results": true, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-03T13:50:02.470Z", "location_count": 54, "location_summary": "Anaheim, California • Duarte, California • Long Beach, California + 46 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04303780" }, { "nct_id": "NCT05374538", "title": "VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "VIC-1911", "type": "DRUG" }, { "name": "sotorasib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vitrac Therapeutics, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2022-11-09", "completion_date": "2023-08-26", "has_results": true, "last_update_posted_date": "2025-05-01", "last_synced_at": "2026-10-03T13:50:02.470Z", "location_count": 5, "location_summary": "Sacramento, California • North Haven, Connecticut • Atlanta, Georgia + 2 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "North Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05374538" }, { "nct_id": "NCT04667234", "title": "Expanded Access of Sotorasib", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Non Small-cell Lung Cancer", "Locally Advanced Unresectable NSCLC", "Locally Advanced Metastatic NSCLC" ], "interventions": [ { "name": "AMG 510", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-03T13:50:02.470Z", "location_count": 30, "location_summary": "Huntsville, Alabama • Anchorage, Alaska • Chandler, Arizona + 27 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Alamosa", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04667234" }, { "nct_id": "NCT06026410", "title": "KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors With HRAS Alterations", "Non Small Cell Lung Cancer (NSCLC)", "Colorectal Cancer (CRC)", "Pancreatic Ductal Adenocarcinoma (PDAC)", "Clear Cell Renal Cell Carcinoma (ccRCC)", "Renal Cell Carcinoma (Kidney Cancer)", "Non Clear Cell Renal Cell Carcinoma (nccRCC)" ], "interventions": [ { "name": "Darlifarnib", "type": "DRUG" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Adagrasib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kura Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2023-10-18", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-10-03T13:50:02.470Z", "location_count": 22, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06026410" }, { "nct_id": "NCT04449874", "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer", "Colorectal Cancer", "Advanced Solid Tumors" ], "interventions": [ { "name": "GDC-6036", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "GDC-1971", "type": "DRUG" }, { "name": "Inavolisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 498, "start_date": "2020-07-29", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-03T13:50:02.470Z", "location_count": 9, "location_summary": "Duarte, California • La Jolla, California • Orange, California + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04449874" }, { "nct_id": "NCT05840510", "title": "Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult", "NSCLC", "Advanced Cancer", "Metastatic Cancer", "Malignant Neoplastic Disease" ], "interventions": [ { "name": "Adagrasib", "type": "DRUG" }, { "name": "nab-Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2023-08-07", "completion_date": "2024-12-27", "has_results": false, "last_update_posted_date": "2025-04-25", "last_synced_at": "2026-10-03T13:50:02.470Z", "location_count": 3, "location_summary": "Cleveland, Ohio • Nashville, Tennessee • Houston, Texas", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05840510" }, { "nct_id": "NCT05313009", "title": "Tarlox and Sotorasib in Patients With KRAS G12C Mutations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Sotorasib and Tarloxotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2022-03-07", "completion_date": "2023-12-31", "has_results": true, "last_update_posted_date": "2025-12-16", "last_synced_at": "2026-10-03T13:50:02.470Z", "location_count": 1, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05313009" }, { "nct_id": "NCT06248606", "title": "Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "NSCLC", "KRAS G12C" ], "interventions": [ { "name": "Adagrasib", "type": "DRUG" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Ryan Gentzler, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-08-06", "completion_date": "2028-02-25", "has_results": false, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-10-03T13:50:02.470Z", "location_count": 3, "location_summary": "Columbus, Ohio • Charlottesville, Virginia • Richmond, Virginia", "locations": [ { "city": "Columbus", "state": "Ohio" }, { "city": "Charlottesville", "state": "Virginia" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06248606" }, { "nct_id": "NCT05118854", "title": "A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "AMG 510", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2022-03-30", "completion_date": "2027-10-20", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-03T13:50:02.470Z", "location_count": 2, "location_summary": "New York, New York • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05118854" }, { "nct_id": "NCT04613596", "title": "Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Advanced Non-Small Cell Lung Cancer", "Metastatic Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Adagrasib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 626, "start_date": "2020-12-02", "completion_date": "2029-10-31", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-03T13:50:02.470Z", "location_count": 220, "location_summary": "Goodyear, Arizona • Prescott Valley, Arizona • Safford, Arizona + 168 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Prescott Valley", "state": "Arizona" }, { "city": "Safford", "state": "Arizona" }, { "city": "Safford", "state": "Arizona" }, { "city": "Safford", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04613596" } ] }